Purpose of Technology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies that target and inactivate the PCSK9 protein in the liver. This drug is intended to reduce the amount of harmful low-density lipoprotein cholesterol (LDL-C) circulating in the bloodstream, thus lowering patient risk for cardiovascular disease (CVD).
Relevant Questions
Is evolocumab effective in lowering cholesterol and decreasing cardiovascular risk?
Is evolocumab safe?
What is the comparative effectiveness of evolocumab with ezetimibe?
Have definitive patient selection criteria been established for patients with hypercholesterolemia or hyperlipidemia treated with evolocumab?
If you have a Hayes login, click here to view the full report on the Knowledge Center.